Techno Drugs (DHA:TECHNODRUG) Operating Income: BDT691 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

DHA:TECHNODRUG Techno Drugs Ltd DHA:TECHNODRUG
37 GF Score
Price BDT42.70
! 5 Warning Signs
View Full Analysis

What is Techno Drugs Operating Income?

Techno Drugs DHA:TECHNODRUG -1.39% 37 Operating Income is BDT691 Mil as of Mar. 2026. GuruFocus rates DHA:TECHNODRUG with a GF Score™ of 37/100. The stock has 5 warning signs investors should review.

Techno Drugs's Operating Income for the three months ended in Mar. 2026 was BDT137 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Mar. 2026 was BDT691 Mil.

Operating Margin % is calculated as Operating Income divided by its Revenue. Techno Drugs's Operating Income for the three months ended in Mar. 2026 was BDT137 Mil. Techno Drugs's Revenue for the three months ended in Mar. 2026 was BDT612 Mil. Therefore, Techno Drugs's Operating Margin % for the quarter that ended in Mar. 2026 was 22.40%.

Techno Drugs's 5-Year average Growth Rate for Operating Margin % was 0.00% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Techno Drugs's annualized ROC % for the quarter that ended in Mar. 2026 was 5.46%. Techno Drugs's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 8.07%.

Techno Drugs  (DHA:TECHNODRUG) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Techno Drugs's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=548.344 * ( 1 - 28.05% )/( (6994.515 + 7457.28)/ 2 )
=394.533508/7225.8975
=5.46 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=7570.591 - 211.708 - ( 364.368 - max(0, 846.838 - 3428.123+364.368))
=6994.515

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=7637.153 - 141.417 - ( 38.456 - max(0, 877.263 - 2867.048+38.456))
=7457.28

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Techno Drugs's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=554.672/( ( (4134.713 + max(2514.221, 0)) + (4762.666 + max(2340.114, 0)) )/ 2 )
=554.672/( ( 6648.934 + 7102.78 )/ 2 )
=554.672/6875.857
=8.07 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(1251.076 + 1022.736 + 789.943) - (211.708 + 0 + 337.826)
=2514.221

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(1160.018 + 1008.887 + 659.687) - (141.417 + 0 + 347.061)
=2340.114

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. Operating Income is also linked to Operating Margin %:

Techno Drugs's Operating Margin % for the quarter that ended in Mar. 2026 is calculated as:

Operating Margin %=Operating Income (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=137.086/611.89
=22.40 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.

Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.

Techno Drugs Operating Income Related Terms

Techno Drugs Operating Income Historical Data

* Premium members only.

The historical data trend for Techno Drugs's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Techno Drugs Operating Income Chart

Techno Drugs Annual Data
Trend Jun24 Jun25
Operating Income
667.11 698.49

Techno Drugs Quarterly Data
Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Operating Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 131.23 230.01 164.58 159.24 137.09
DHA:TECHNODRUG
37GF Score
Techno Drugs Ltd DHA:TECHNODRUG
Operating Income is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Techno Drugs Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was BDT691 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Operating Income →
What does a Operating Income of BDT691 Mil mean?
Techno Drugs (DHA:TECHNODRUG) has a Operating Income of BDT691 Mil as of Mar. 2026. Operating Income equals sales less all operating expenses. It is linked to EBIT. View historical data on Techno Drugs and its competitors.
Is Techno Drugs' Operating Income too high?
Techno Drugs' current Operating Income is BDT691 Mil. Overall, Techno Drugs has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does Techno Drugs' Operating Income compare to ZTS and UTHR?
Techno Drugs' Operating Income of BDT691 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Income for a Drug Manufacturers company?
A good Operating Income depends on the Drug Manufacturers industry context. However, Operating Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Income mean?
A high Operating Income can signal that a stock is expensive relative to its fundamentals. Operating Income equals sales less all operating expenses. It is linked to EBIT. View historical data on Techno Drugs and its competitors. Techno Drugs's current Operating Income is BDT691 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Techno Drugs stock overvalued right now?
Techno Drugs (DHA:TECHNODRUG) has a current Operating Income of BDT691 Mil. The current Operating Income is BDT691 Mil. Techno Drugs' overall GF Score™ is 37/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Income calculated?
Operating Income is calculated from a company's financial statements. For Techno Drugs (DHA:TECHNODRUG), the current Operating Income is BDT691 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Techno Drugs Business Description

Address 31 Segun Bagicha, J K Tower, Dhaka, BGD, 1000
Techno Drugs Ltd is a pharmaceutical company. The company manufactures medicines for the healthcare market with quality products, a distribution channel, and doctor-patient acceptance. The company is also engaged in production of Anti-Cancer medicines and medicines for therapeutic areas like oncology, cardiovascular, diabetes, immune suppressor, anesthetics, life-saving antibiotics & contrast media in Bangladesh. The product portfolio of the company include Algicar Plus, Amoclav Forte, Adesol Oral Solution, Aminovet Injection, Apegestrol Tab, Docetex 20 Inj, and others.
37GF Score

Get the complete analysis for DHA:TECHNODRUG

Operating Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

BDT42.70
Price